3KC533 – Heterophilic Blocking Reagent (HBR), 20 mg/ml => Directional Insert | SDS
It contains specific murine immunoglobulins that block the heterophilic interaction by active binding to the heterophilic antibodies, which are capable of cross-linking the capture and the detection antibodies used in the immunoassay, resulting in false positive readings. The attachment of HBR-1 to the heterophilic antibodies blocks this cross-linking, and eliminates the interference caused by the heterophilic antibodies in the humoral fluids. In addition to its active blocking, this product is also characteristic of its passive blockage of the heterophilic interaction as well. The HBR is a liquid reagent with a protein concentration of 20 ± 2 mg/ml. The immunoglobulins are dissolved in a phosphate buffer with a pH of 7.4. The immunoglobulins in this product are at a purity of greater than or equal to 95% as shown by SDS-PAGE.
3KC534-075 – Heterophilic Blocking Reagent (HBR), 2mg/ml => Directional Insert | SDS
The HBR contains immunoglobulins of murine origin with specific binders that neutralize by active attachment to the heterophilic antibody. The attachment of HBR to the heterophilic antibodies renders the heterophilic antibodies incapable of cross-linking the capture and the label antibodies in the immunoassay. The HBR is a liquid reagent with a protein concentration of 2 ± 0.1 mg/ml. The immunoglobulins are dissolved in a phosphate buffer with a pH of 7.2 – 7.6. The immunoglobulins in the HBR are at a purity of greater than or equal to 95%.
3KC534 – Heterophilic Blocking Reagent 1 (HBR 1), 2mg/ml => Directional Insert | SDS
The HBR contains immunoglobulins of murine origin with specific binders that neutralize by active attachment to the heterophilic antibody. The attachment of HBR to the heterophilic antibodies renders the heterophilic antibodies incapable of cross-linking the capture and the label antibodies in the immunoassay. The HBR is a liquid reagent with a protein concentration of 2 ± 0.1 mg/ml. The immunoglobulins are dissolved in a phosphate buffer with a pH of 7.0 – 7.4. The immunoglobulins in the HBR are at a purity of greater than or equal to 95%.
3BX484 – HBR-1 , Non Purified => SDS
This product contains the same heterophilic blocking components of HBR-1 in a non-purified form at a concentration of 2-3g/dL. Therefore, its total protein concentration is higher than HBR-1 Purified due to presence of some non-HBR proteins. Some customers prefer this product that further reduces the non-specific interaction which can lead to falsely elevated results.
3KC535 – HBR-2 , Purified => SDS
This product represents a variation in formulation with similar essential characteristics compared to HBR-1-Purified. It has a concentration of 7-8 mg/ml.
3KC701 – HBR-3 , Purified => SDS
Each vial contains approximately 4 mg of immunoglobulins. This product represents a variation in formulation with similar essential characteristics compared to HBR-1 Purified. The special formulation is designed to enhance its blocking capability at a lower concentration of immunoglobulins.
3KC542 – HBR-6 , Purified => SDS
Each vial of HBR-6 contains approximately 10 mg of immunoglobulins. This HBR-6 is specially formulated to enhance its heterophilic blocking ability. The immunoglobulins in this reagent are at a purity of greater than or equal to 95%.
3KC564 – HBR-9 , Purified => SDS
The HBR-9 is also one of our newly formulated products developed as an alternative for the HBR Plus, 3KC545. It contains immunoglobulins with different characteristics. It is specially formulated for application for immunoassays in which both the capture and detection antibodies are of murine origin. Like HBR Plus, this product is characteristics for its active as well as passive blocking efficacy. Each vial of this product contains approximately 20 mg of immunoglobulins, which are at a purity of greater than 90%.
3KC565 – HBR-11 , Purified => SDS
The HBR-11 is also one of our newly formulated products. This product is formulated with murine immunoglobulins. In addition to the products listed above, the HBR-11 provides our customers with more selection for heterophilic blockage. Each vial of this product contains approximately 20 mg of immunoglobulins, which are at a purity of greater than 90%.
3KC545 – HBR-Plus , Purified => SDS
The HBR Plus is one of our newly formulated products developed as an alternative for HBR-1. This product is compounded with immunoglobulins with different characteristics. Therefore, in addition to its active blocking characteristics, the special formulation and production procedures enhance its efficacy in its passive blocking ability as well. Each vial of this HBR Plus contains approximately 20 mg of immunoglobulins.

3IX761 – Nonspecific Antibody Blocking Tube (NABT) => Directional Insert
The NABT contains immunoglobulins. The non-specific antibodies in the serum or plasma samples bind to these immunoglobulins and are blocked from interfering in antibody detection immunoassays. Each tube contains enough reagent to inactivate the non-specific antibodies in 500 ?L of sample. The reagent is in the form of a lyophilized pellet at the bottom of the tube. The NABT allows for the rapid and simple elimination of false positive non-specific antibody interference in plasma or serum for detection assays (i.e., anti-HCV, HIV, Toxoplasmosis, Rubella, CMV. Herpes. Tg, TPO, etc.). The NABT is used as a sample treatment in preparation for testing. It can either be used in conjunction with the initial assay or in a secondary confirmation assay. NABT represents a sample pretreatment/second assay intended to confirm or disqualify the original FDA licensed non pretreatment assay result. The assay result from the pretreatment is NEVER TO BE USED AS A REPORTABLE RESULT. The pretreatment is only a confirmation aid designed to assist the lab to know whether to report the original non pretreatment assay result. In other words, if the pretreatment assay result is the same as the original assay result the original result is reported. However, if the pretreatment sample assay result is lower than the original result, the original result is not reported and the sample is submitted for further study for potential false positive assay interference.
3IX762 – Heterophilic Blocking Tubes (HBT) => Directional Insert
The HBT contains a unique blocking reagent composed of specific binders which inactivate heterophilic antibodies. Once the specific binders have bound to the heterophilic antibodies, the antibodies are no longer able to cause immunoassay interference. The reagent is in the form of a lyophilized pellet at the bottom of the tube. Each tube contains enough reagent to inactivate the heterophilic antibodies in 500 ?L of sample. The HBT allows for the rapid and simple elimination of false positive heterophilic interference in plasma or serum for immunoassays (i.e., FSH, LH, Prolactin, TSH, Ferritin, CEA, AFP, hCG, HBsAg, CK-MB, CA 1251, CA 19-9 , NSE, etc.). HBT represents a sample pretreatment/second assay intended to confirm or disqualify the original FDA licensed non pretreatment assay result. The assay result from the pretreatment is NEVER TO BE USED AS A REPORTABLE RESULT. The pretreatment is only a confirmation aid designed to assist the lab to know whether to report the original non pretreatment assay result. In other words, if the pretreatment assay result is the same as the original assay result the original result is reported. However, if the pretreatment sample assay result is lower than the original result, the original result is not reported and the sample is submitted for further study for potential false positive assay interference.